Palatin Technologies (NYSEAMERICAN:PTN) posted its quarterly earnings data on Tuesday. The biopharmaceutical company reported ($0.02) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.01) by ($0.01), MarketWatch Earnings reports. During the same period last year, the firm posted ($0.02) EPS.
NYSEAMERICAN:PTN opened at $0.43 on Friday. Palatin Technologies has a 52 week low of $0.36 and a 52 week high of $0.84.
Separately, Zacks Investment Research upgraded shares of Palatin Technologies from a “sell” rating to a “hold” rating in a report on Tuesday, September 29th.
Palatin Technologies, Inc, a specialized biopharmaceutical company, develops targeted receptor-specific therapeutics for the treatment of various diseases in the United States. The company's lead product is Vyleesi, a melanocortin receptor agonist for the treatment of premenopausal women with acquired, generalized hypoactive sexual desire disorder.
Read More: What causes a recession?
Receive News & Ratings for Palatin Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Palatin Technologies and related companies with MarketBeat.com's FREE daily email newsletter.